Researchers are working on a redesigned pump that could offer hope for those with HFpEF, which accounts for about 32 million heart failure cases globally.

Roth Capital Markets analyst Jonathan Aschoff has maintained his “Buy” rating and US$30.00 price target on Tenax Therapeutics ...

Savara advances BLA plans with strong molgramostim data, large aPAP market potential, and a reinforced cash position. Find ...

If this new pump proves successful in clinical testing, it could revolutionize heart failure treatment, offering renewed ...